Augmenting Pre-Operative Risk of Recurrence Stratification in DTC
R. Michael Tuttle, MD, discusses a study that looked at augmenting pre-operative risk of recurrence stratification in differentiated thyroid carcinoma.
Clinical Pearls
R. Michael Tuttle, MD, professor of medicine, Memorial Sloan Kettering Cancer Center, discusses a study that looked at augmenting pre-operative risk of recurrence stratification in differentiated thyroid carcinoma.
- This study set out to determine if data obtained during pre-operative nodule biopsy could be used to augment risk stratification.
- The ensemble classifier correctly identified 72.4% (21/29) of low risk tumors and 82.6% (43/52) of intermediate/high risk tumors.
- This represents another piece of information to help a physician decide on the proper approach to surgery.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
